Retatrutide CAS NO.2381089-83-2

Mechanism of Action

The mechanism of action of Retatrutide is characterized by its unique triple-agonist profile, which integrates the effects of three key metabolic hormones. By activating GLP-1 receptors, it enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner while slowing gastric emptying to increase satiety; through GIP receptor agonism, it improves insulin sensitivity and may potentiate the effects on adipose tissue; and critically, by activating the glucagon receptor, it increases energy expenditure and promotes lipolysis, thereby creating a synergistic effect that not only reduces appetite but also actively burns stored fat.

Product Indications

Retatrutide is indicated for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as well as for the management of type 2 diabetes mellitus. It is particularly suitable for patients seeking substantial weight loss beyond what is typically achievable with lifestyle modifications or first-line pharmacotherapies, including those who may be considering bariatric surgery but prefer a non-surgical alternative, and individuals requiring robust glycemic control alongside significant body weight reduction.

Clinical Efficacy of Product

Clinical trial data, notably from the Phase 2 TRIUMPH study, demonstrate that Retatrutide achieves unprecedented levels of weight reduction, with up to 24.2% mean body weight loss at 48 weeks at the 12 mg dose, and over 30% weight loss observed in a significant proportion of participants at 72 weeks. For glycemic control, it achieved HbA1c reductions of up to 2.02%, significantly outperforming active comparators like dulaglutide. Furthermore, the product has shown efficacy in reducing liver fat content and improving cardiometabolic markers such as blood pressure and lipids, establishing it as a potent agent for comprehensive metabolic health.

Certificate

• [v] 1. A rigorous quality management system
• [v] 2. Batch traceability and stability data
• [v] 3. Professional laboratory testing and validation
• [v] 4. Compliance with international trade standards

Delivery & Shipping

Professional and Secure Packaging

Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation. We can also customize packaging according to customer needs.

Shipping Methods

Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.

HotTags: Retatrutide, TripleAgonist, ObesityTreatment, Type2Diabetes, WeightLossJourney, GLP1Agonist, MetabolicHealth, EliLilly, ClinicalTrials, NewDrug, FatLoss, IncretinTherapy Supplier, Manufacturer, Bulk order, Pharmaceutical.

Retatrutide is an experimental medication being studied for obesity and metabolic disease, and it has drawn attention for its impressive weight-loss effects in clinical trials. However, it does not “burn fat” in the simple sense of directly destroying fat tissue. Instead, it works through complex hormonal pathways that lead the body to reduce fat stores over time.

Retatrutide activates three key hormone receptors: GLP-1, GIP, and glucagon. These hormones regulate appetite, blood sugar, and energy balance. By stimulating GLP-1 and GIP pathways—similar to drugs like Tirzepatide—it significantly reduces hunger and food intake, helping people consume fewer calories. At the same time, its glucagon receptor activity may slightly increase energy expenditure, meaning the body uses more calories at rest. This combination creates a sustained calorie deficit, which leads to fat loss.

Clinical studies have shown that people taking retatrutide can lose a substantial percentage of their body weight, much of which comes from fat mass rather than muscle. This distinguishes it from crash dieting, where muscle loss can be significant. The drug also improves metabolic markers such as insulin sensitivity and lipid levels, suggesting that the fat loss is accompanied by broader health benefits.

Retatrutide is an investigational therapy that has shown a range of promising benefits in early clinical studies, particularly for people with obesity and metabolic disorders. Its unique mechanism targets three hormone receptors—GLP-1, GIP, and glucagon—allowing it to influence multiple aspects of energy balance and metabolism at the same time.

One of the most notable benefits of retatrutide is substantial weight loss. In clinical trials, participants have experienced significant reductions in body weight, often exceeding what has been observed with earlier medications such as Tirzepatide. This weight loss is largely driven by decreased appetite, increased feelings of fullness, and reduced overall calorie intake. In addition, the drug may modestly increase energy expenditure through its glucagon-related effects, further supporting fat reduction.

Beyond weight management, retatrutide has demonstrated improvements in metabolic health. It can help lower blood glucose levels, making it potentially useful for individuals with Type 2 Diabetes or insulin resistance. Patients in studies have also shown better insulin sensitivity and improved lipid profiles, including reductions in triglycerides and LDL cholesterol.

Retatrutide is still an investigational drug, so you generally cannot obtain it through standard prescriptions or pharmacies at this time. Unlike approved medications such as Tirzepatide, retatrutide has not yet received full regulatory approval from agencies like the U.S. Food and Drug Administration. This means it is not legally available for routine clinical use.

The primary way to access retatrutide right now is through participation in clinical trials. These studies are conducted to evaluate the drug’s safety, effectiveness, and appropriate dosing. Individuals who meet specific eligibility criteria—such as having obesity or Type 2 Diabetes—may be able to enroll. Clinical trials are typically run by research hospitals, universities, or pharmaceutical companies, and participants are closely monitored by medical professionals throughout the study.